Trial Profile
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 01 Jul 2020 Status changed from recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 1 Jun 2017 to 1 Dec 2020.
- 16 Jan 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2019.